Premium
Dual‐Action Cancer Therapy with Targeted Porous Silicon Nanovectors
Author(s) -
CifuentesRius Anna,
Ivask Angela,
Sporleder Ester,
Kaur Ishdeep,
Assan Yasmin,
Rao Shasha,
Warther David,
Prestidge Clive A.,
Durand JeanOlivier,
Voelcker Nicolas H.
Publication year - 2017
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201701201
Subject(s) - nanocarriers , nanoclusters , cytotoxicity , nanotechnology , drug delivery , materials science , drug , nanomedicine , targeted drug delivery , cancer cell , drug carrier , site of action , cancer , cancer research , nanoparticle , pharmacology , chemistry , medicine , in vitro , biochemistry
There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody‐functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two‐stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.